PDF(Pubmed)
Abstract：
Interstitial cystitis/bladder pain Syndrome (IC/BPS) remains a mysterious and intricate urological disorder, presenting significant challenges to healthcare providers. Traditional guidelines for IC/BPS follow a hierarchical model based on symptom severity, advocating for conservative interventions as the initial step, followed by oral pharmacotherapy, intravesical treatments, and, in refractory cases, invasive surgical procedures. This approach embraces a multi-tiered strategy. However, the evolving understanding that IC/BPS represents a paroxysmal chronic pain syndrome, often involving extravesical manifestations and different subtypes, calls for a departure from this uniform approach. This review provides insights into recent advancements in experimental strategies in animal models and human studies. The identified therapeutic approaches fall into four categories: (i) anti-inflammation and anti-angiogenesis using monoclonal antibodies or immune modulation, (ii) regenerative medicine, including stem cell therapy, platelet-rich plasma, and low-intensity extracorporeal shock wave therapy, (iii) drug delivery systems leveraging nanotechnology, and (iv) drug delivery systems assisted by energy devices. Future investigations will require a broader range of animal models, studies on human bladder tissues, and well-designed clinical trials to establish the efficacy and safety of these therapeutic interventions.
摘要：
间质性膀胱炎/膀胱疼痛综合征（IC/BPS）仍然是一种神秘而复杂的泌尿系统疾病，给医疗保健提供者带来重大挑战。传统的IC/BPS指南遵循基于症状严重程度的分层模型，倡导保守干预作为第一步，其次是口服药物治疗，膀胱内治疗,and,在难治性病例中，侵入性外科手术.这种方法包括多层次战略。然而,对IC/BPS代表阵发性慢性疼痛综合征的理解不断发展，通常涉及奢侈的表现和不同的亚型，呼吁偏离这种统一的方法。这篇综述提供了有关动物模型和人类研究实验策略最新进展的见解。确定的治疗方法分为四类：（i）使用单克隆抗体或免疫调节的抗炎和抗血管生成，(ii)再生医学，包括干细胞治疗,富血小板血浆,和低强度体外冲击波疗法，(iii)利用纳米技术的药物输送系统，和(iv)由能量装置辅助的药物递送系统。未来的研究将需要更广泛的动物模型，对人类膀胱组织的研究，和精心设计的临床试验，以确定这些治疗干预措施的有效性和安全性。
